



Board

Cover Sheet

Item : Outcomes of engagement in Overprescribing project Enclosure: C

Title:	SEL Overprescribing project : patient engagement				
Meeting Date:	19 th March 2024				
Author:	Lelly Oboh Lead Pharmacist Overprescribing, SEL ICS				
Executive Lead:	 Senior responsible officers Vanessa Burgess, Chief Pharmacist, Director Medicines and Long-Term Conditions, SEL ICS Toby Garrood, Joint Medical Director SEL ICS 				
Purpose of paper:	To share preliminary findings, outcomes, and successes from the patient engagement work	Update / Information	x		
	To give an overview of how we have engaged with the public (patients and communities,	Discussion			
	 particularly those experiencing inequalities) in various ways to deliver the objectives of the project 1. In a timely way at the earliest opportunity 2. In a meaningful and appropriate way 3. Listened to views from diverse communities including those experiencing health inequalities and people with relevant lived experience 4. Considered insight and views and demonstrated how these have influenced decision making 5. Provided feedback to those who have given their views (partially) 	Decision			
Summary of main points:	 The project Engaged with well over 300 residents (and carers) from diverse groups across the 6 Boroughs through various networks and methods Demonstrates that members of the public are willing to engage, be involved and can contribute to reducing overprescribing Confirms that we need a whole- systems approach to tackle overprescribing because of the interdependencies and complexities, and the patient perspective is necessary for improving practice/service at organisation and individual levels 				

1

Chair: Richard Douglas CB

Chief Executive Officer: Andrew Bland

We are collaborative • We are caring • We are inclusive • We are innovative





Potential Conflicts of Interest	 Feedback and outputs show that some solutions can be put in place in the short to medium term, however others will require longer term solutions as we move towards more co-design and co-production with our patients Feedback from the work including commendation from senior NHSE leaders have led to the conclusion that we must continue to engage with patients to tackle overprescribing 				
Relevant to the	Bexley		x	Bromley	x
following	Greenwich		x	Lambeth	x
Boroughs	Lewisham		x	Southwark	x
	Equality Impact Evidence of higher prevale & Black ethnicities (national				igher deprivation, Asian
	Financial Impact	Funding for the Overprescribing lead pharmacist post Oct 2022-Mar 2024			
Other Engagement	Public Engagement	 2022-Mar 2024 In collaboration with the SEL patient engagement lead and team Web platform <u>Tell us about your experience</u> of taking many medicines Let's Talk Health and Care South East London (letstalkhealthandcareselondon.org), Overprescribing patient webinar Overprescribing patient survey Overprescribing chat forum Community groups outreach to Southwark Carers Bromley Asian Cultural Association (BACA) 			r experience <u>s Talk Health</u> <u>.org)</u> , r ociation (BACA) tre reenwich Centre (LICC) n Group, Greenwich Carers Forum eth ewisham vith Public Health

2

Chair: Richard Douglas CB

Chief Executive Officer: Andrew Bland

We are collaborative • We are caring • We are inclusive • We are innovative





		 Health Innovation Network (HIN), Opioid QI Collaborative and Experienced Based Co-design project 	
	Other Committee Discussion/ Engagement	 The SEL Overprescribing Working Group (OPWG) has representatives from all parts of the system including Public Health, Acute, Mental Health and Community Trusts, PCNs, SEL Personalised care, Patient engagement, Local Care Partnerships Medicines Optimisation Teams, Health Innovation Network (HIN), Kings College London SEL Integrated Medicines Optimisation Committee (IMOC) (plan approved) SEL Integrated Pharmacy Stakeholder Group (IPSG) SEL Clinical and Care Professional Committee Lambeth Together Medicines and Clinical Pathways Group (MCLiP) 	
Recommendation:	The EAC is asked to note the breadth and depth of patient engagement activities undertaken, the preliminary findings, outputs and outcomes from the work as well as the next steps to incorporate the learning and continue public (patient) engagement to tackle overprescribing post March 2024 Also to offer suggestions on how best we continue to engage with the public		

Chair: Richard Douglas CB

We are collaborative • We are caring • We are inclusive • We are innovative